| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
585,690,000 |
| Market
Cap: |
178.65(B) |
| Last
Volume: |
1,924,998 |
Avg
Vol: |
2,723,980 |
| 52
Week Range: |
$217.36 - $324.56 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 100 |
|
S&P 500 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 499 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Amgen is a biotechnology company that focuses on discovering, developing, manufacturing and delivering human therapeutics. Co.'s principal products are Enbrel® (etanercept), Prolia® (denosumab), Otezla® (apremilast), XGEVA® (denosumab), Neulasta® (pegfilgrastim), Aranesp® (darbepoetin alfa), Repatha® (evolocumab), KYPROLIS® (carfilzomib) and Nplate® (romiplostim). Co. also markets a number of other products, including among other, MVASI® (bevacizumab-awwb), Vectibix® (panitumumab), KANJINTI® (trastuzumab-anns), EVENITY® (romosozumab-aqqg), EPOGEN® (epoetin alfa), BLINCYTO® (blinatumomab), AMGEVITA™ (adalimumab), Aimovig® (erenumab-aooe), Parsabiv® (etelcalcetide) and NEUPOGEN® (filgrastim).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,117 |
2,117 |
23,771 |
31,503 |
| Total Sell Value |
$662,802 |
$662,802 |
$6,471,520 |
$8,438,219 |
| Total People Sold |
1 |
1 |
3 |
6 |
| Total Sell Transactions |
1 |
1 |
4 |
8 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meline David W |
EVP & CFO |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$83,138 |
D/D |
(529) |
50,690 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$379,856 |
D/D |
(2,417) |
350,732 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$93,982 |
D/D |
(598) |
187,973 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$80,623 |
D/D |
(513) |
45,442 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2017-01-30 |
4 |
D |
$157.16 |
$17,759 |
D/D |
(113) |
20,557 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$91,467 |
D/D |
(582) |
89,583 |
|
- |
|
| Bradway Robert A |
Chairman, CEO and President |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$420,089 |
D/D |
(2,673) |
353,149 |
|
- |
|
| Hooper Anthony C |
EVP, Global Commercial Ops. |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$165,489 |
D/D |
(1,053) |
188,571 |
|
- |
|
| Harper Sean E |
EVP, Research & Development |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$165,961 |
D/D |
(1,056) |
45,955 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2017-01-28 |
4 |
D |
$157.16 |
$43,848 |
D/D |
(279) |
20,670 |
|
- |
|
| Johnston Lori A |
SVP, HROfficer |
• – – |
2016-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,528 |
|
- |
|
| Kullman Ellen Jamison |
Director |
• • – |
2016-11-01 |
4 |
A |
$0.00 |
$0 |
D/D |
355 |
410 |
|
- |
|
| Patton Cynthia M |
SVP & CCO |
• • – |
2016-10-26 |
4 |
D |
$157.90 |
$164,684 |
D/D |
(1,043) |
20,924 |
|
- |
|
| Mcnamee Brian M |
EVP |
• • – |
2016-10-25 |
4 |
D |
$158.76 |
$334,825 |
D/D |
(2,109) |
90,078 |
|
- |
|
| Kullman Ellen Jamison |
Director |
– • – |
2016-10-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55 |
|
- |
|
| De Carbonnel Francois |
Director |
• • – |
2016-09-09 |
4 |
D |
$170.97 |
$445,206 |
D/D |
(2,604) |
18,567 |
|
- |
|
| De Carbonnel Francois |
Director |
• • – |
2016-09-09 |
4 |
OE |
$71.64 |
$358,200 |
D/D |
5,000 |
21,171 |
|
- |
|
| Graham Jonathan P |
SVP, Gen. Counsel & Secy. |
• • – |
2016-08-04 |
4 |
D |
$173.43 |
$1,139,435 |
D/D |
(6,570) |
46,748 |
|
- |
|
| Such Annette Louise |
VP, Finance and CAO |
• • – |
2016-08-02 |
4 |
S |
$174.59 |
$523,758 |
D/D |
(3,000) |
7,183 |
|
- |
|
| Meline David W |
EVP & CFO |
• • – |
2016-08-01 |
4 |
D |
$172.03 |
$1,163,955 |
D/D |
(6,766) |
50,741 |
|
- |
|
| Such Annette Louise |
VP, Finance and CAO |
• • – |
2016-08-01 |
4 |
D |
$172.03 |
$44,384 |
D/D |
(258) |
10,183 |
|
- |
|
| Santos Esteban |
EVP, OperationsOfficer |
• – – |
2016-07-25 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
680 |
|
- |
|
| Santos Esteban |
EVP, OperationsOfficer |
• – – |
2016-07-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,158 |
|
- |
|
| Pelham Judith C |
Director |
• • – |
2016-06-08 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,167 |
10,002 |
|
- |
|
| Balachandran Madhavan |
EVP, Operations |
• • – |
2016-05-04 |
4 |
S |
$154.12 |
$4,623,624 |
I/I |
(30,000) |
55,996 |
|
- |
|
2206 Records found
|
|
Page 29 of 89 |
|
|
0.67 (0.22%) 
